Back to search

Article

Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis: a mathematical modeling analysis

2023-07-31

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Emerging evidence suggests that shortened, simplified treatment regimens for rifampicin-resistant tuberculosis (RR-TB) can achieve comparable end-of-treatment outcomes to longer regimens. We compared a 6-month regimen containing bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) to a standard of care strategy using a 9- or 18-month regimen depending on whether fluoro...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
2cf7b551-7ade-57dd-b51f-76976dbfe8f0
DOI
10.1101/2023.07.28.23293104
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis: a mathematical modeling analysisDOI 10.1101/2023.07.28.23293104
Select a neighboring publication to make it the new centre.